Hans Joachim Bochtler

Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA

Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark.

Part of Pfizer Inc., Coley Pharmaceutical GmbH is a German company that provides research and development in the field of natural sciences, engineering, agricultural sciences and medicine. The company is based in Berlin, Germany. The company was founded by Heather L. Davis.

BIO Deutschland is a business association for the biotechnology industry. The private company is based in Berlin, Germany. The German company was founded by Peter Heinrich, Horst Domdey. Viola Bronsema has been the CEO of the company since 2006.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark.

Lindis Blood Care GmbH engages in the development and manufacture of autologous blood transfusion devices. It specializes in blood transfusion and intraoperative blood salvage. The company was founded by Horst Lindhofer and Franzpeter Bracht in January 2018 and is headquartered in Hennigsdorf, Germany.

Part of Ensoma, Inc., Twelve Bio is a Danish company that seeks to expand the breadth of CRISPR-based gene-editing medicines to transform the management of serious diseases. The company is based in Copenhagen, Denmark. Twelve Bio uses its insights into nuclease structure and function to design highly precise and nimble CRISPR-Cas12 candidates for therapeutic application. The company will continuously advance its platform and understanding of Cas enzymes to address the needs of patients worldwide. The company was founded by Stefano Stella, Guillermo Montoya. Twelve Bio was acquired by Ensoma, Inc. on February 09, 2023.